Joana Antunes

Joana Antunes

Auto-generated profile, based on publicly available information

Joana Antunes

Serviço de Dermatologia, Unidade Local de Saúde Santa Maria (ULSSM), Hospital de Santa Maria, Lisboa, Portugal

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in Dermatology Online Journal
Verified
Journal Article
Closed access
JAJoana Antunes
Joana Antunes
DPDavid Pacheco
David Pacheco
RTRita Travassos
Rita Travassos
HSHortênsia Sequeira
Hortênsia Sequeira
PFPaulo Filipe
Paulo Filipe
MMManuel Sacramento Marques
Manuel Sacramento Marques
Author(s): Antunes, Joana; Pacheco, David; Travassos, Rita; Sequeira, Hortênsia; Filipe, Paulo; Marques, Manuel Sacramento

8 January 2025 in Acta Dermato-Venereologica
Verified
Journal Article
Open access
PDF file
GAGustavo Almeida-Silva
Gustavo Almeida-Silva
JAJoana Antunes
Joana Antunes
IAInês Tribolet de Abreu
Inês Tribolet de Abreu
FMFilipe Monteiro
Filipe Monteiro
PVPedro Vasconcelos
Pedro Vasconcelos
PFPaulo Filipe
Paulo Filipe
Sweet’s syndrome (or acute febrile dermatosis) is a neutrophilic dermatosis with a characteristic presentation encompassing specific clinical (fever and erythemato-violaceous oedematous papules, plaques and nodules), laboratory (neutrophilia and increased inflammatory markers), and histological (dermal neutrophilic infiltrate without vasculitis) features. Its pathophysiology is poorly understood but there seems to be an auto-inflammatory component related to mutations in inflammasome genes. It has been subdivided into its classic form, malignancy-associated, and drug-induced, according to its aetiology. The condition usually responds rapidly to steroid therapy, but recurrences are common. This report presents an extremely rare case of hydroxychloroquine-induced Sweet’s syndrome, plus a review of the literature, which encompasses 3 previous cases of Sweet’s syndrome induced by hydroxychloroquine and 1 induced by chloroquine. Despite being relatively easy to diagnose, aetiological investigation poses challenges to the clinician, especially in the elderly population, as several confounding factors might be present. Further studies are necessary to shed light on the pathophysiology behind this entity, to further facilitate diagnostic workup and treatment strategies.

17 July 2025 in International Journal of Dermatology
Verified
Journal Article
Closed access
TTTiago Torres
Tiago Torres
BGBarbara Vieira Granja
Barbara Vieira Granja
RGRita Guedes
Rita Guedes
JAJoana Antunes
Joana Antunes
MLMartim Luz
Martim Luz
PFPaulo Ferreira
Paulo Ferreira

30 December 2021 in Anais Brasileiros de Dermatologia
Verified
Journal Article
Open access
CBCláudia Brazão
Cláudia Brazão
MAMiguel Alpalhão
Miguel Alpalhão
MAMarta Aguado-Lobo
Marta Aguado-Lobo
JAJoana Antunes
Joana Antunes
LSLuis Soares-de-Almeida
Luis Soares-de-Almeida
PFPaulo Filipe
Paulo Filipe

Verified
Journal Article
Open access
PDF file
GAGustavo Almeida-Silva
Gustavo Almeida-Silva
JAJoana Antunes
Joana Antunes
JFJoão António Ferreira
João António Ferreira
PFPaulo Filipe
Paulo Filipe
Background/Objectives: Psoriasis is a chronic immune-mediated inflammatory disease increasingly recognized as a systemic disorder associated with significant metabolic and cardiovascular comorbidities. Among these, obesity (defined as BMI > 30 kg/m2) plays a pivotal role, acting both as a risk factor for psoriasis development and as a modifier of disease severity, clinical phenotype, and therapeutic response. The relationship between psoriasis and obesity is bidirectional and sustained by shared inflammatory and metabolic pathways. This review aims to provide a comprehensive and updated synthesis of the epidemiological association between psoriasis and obesity, to elucidate the underlying pathophysiological mechanisms, and to discuss the clinical and therapeutic implications of excess body weight in psoriasis management. Methods: A narrative review of the literature was conducted, including epidemiological studies, mechanistic research, clinical trials, and real-world evidence addressing the interplay between psoriasis and obesity. Relevant data were identified from peer-reviewed publications focusing on inflammatory pathways, metabolic dysfunction, cardiovascular risk, and treatment outcomes in obese patients with psoriasis. The graphical figures included in this manuscript were created with the assistance of a large language model–based image-generation tool, ChatGPT-5 by OpenAI, using author-defined prompts. The prompts requested schematic medical illustrations summarizing the pathophysiological links between obesity and psoriasis, including adipose tissue dysfunction, adipokine imbalance, systemic inflammation, and activation of the IL-23/Th17 axis. For the therapeutic algorithm, the prompt requested a stepwise clinical flowchart for obese patients with psoriasis, including BMI assessment, comorbidity screening, universal weight-management measures, psoriasis severity stratification, obesity-adapted biologic selection, and management of suboptimal response. The generated images were subsequently reviewed, edited, and approved by the authors to ensure scientific accuracy, clarity, and consistency with the manuscript content. Results: Epidemiological evidence consistently demonstrates a higher prevalence of obesity among patients with psoriasis, with obesity independently associated with increased disease severity. Shared mechanisms include adipose tissue–driven cytokine production, dysregulated adipokine secretion, insulin resistance, endothelial dysfunction, and activation of the IL-23/Th17 axis, collectively contributing to systemic inflammation and accelerated atherogenesis. Obesity negatively impacts the efficacy, pharmacokinetics, and long-term drug survival of conventional systemic agents and biologic therapies, leading to suboptimal clinical outcomes. Conclusions: Obesity is a key determinant of psoriasis burden, influencing disease expression, comorbidities, and therapeutic response. Integrating weight reduction strategies into personalized psoriasis management may improve both dermatological outcomes and overall cardiometabolic health, supporting a holistic approach to patient care.

5 January 2026 in The Journal of Dermatology
Verified
Journal Article
Closed access
JCJoão Mendes Cravo
João Mendes Cravo
JVJoana Vieitez‐Frade
Joana Vieitez‐Frade
GAGustavo Almeida-Silva
Gustavo Almeida-Silva
MCMadalena Correia
Madalena Correia
CGCatarina Gregório
Catarina Gregório
JAJoana Antunes
Joana Antunes